Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application
The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes.
Authors
- Rafael López‐López (ORCID: https://orcid.org/0000-0003-1315-655X)
- Santiago Domingo (ORCID: https://orcid.org/0000-0002-8355-3369)
- Antonio Gil‐Moreno (ORCID: https://orcid.org/0000-0003-1106-5590)
- Virginia García-Pineda (ORCID: https://orcid.org/0000-0002-6434-3630)
- Carlos Casas‐Arozamena (ORCID: https://orcid.org/0000-0002-3279-2482)
- Miguel Abal (ORCID: https://orcid.org/0000-0003-3533-7781)
- Pablo Padilla-Iserte (ORCID: https://orcid.org/0000-0003-0524-6213)
- Eva Díaz
- Alicia Hernández (ORCID: https://orcid.org/0000-0002-2494-3041)
- Mónica Pamies Serrano
- Alexandra Cortegoso (ORCID: https://orcid.org/0000-0003-4098-9266)
- Gema Moreno‐Bueno (ORCID: https://orcid.org/0000-0002-5030-6687)
- Laura Muinelo‐Romay (ORCID: https://orcid.org/0000-0002-7456-7531)
- Victoria Sampayo
- Juan Ruiz‐Bañobre
- Xavier Matías‐Guiu (ORCID: https://orcid.org/0000-0002-7201-6605)
- Silvia Cabrera
- Teresa Curiel (ORCID: https://orcid.org/0000-0003-2791-9554)
- Efigenia Arias (ORCID: https://orcid.org/0000-0001-8744-9502)
- Sara S. Oltra (ORCID: https://orcid.org/0000-0002-0128-6106)
- Juan Cueva (ORCID: https://orcid.org/0000-0003-1389-4595)
- Alicia Abalo (ORCID: https://orcid.org/0000-0002-5075-0251)
- Cristian P. Moiola (ORCID: https://orcid.org/0000-0001-7218-0184)
- Eva Colás (ORCID: https://orcid.org/0000-0003-0302-4828)
- Marta Arnáez (ORCID: https://orcid.org/0000-0003-2706-7865)
- Ana Vilar
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Universidade de Santiago de Compostela (ES)
- Hospital Universitario La Paz (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Instituto de Investigaciones Biomédicas Sols-Morreale (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- MD Anderson Cancer Center Madrid (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1186/s13046-024-03158-w
- Citations
- 18
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 5.13
Funders
- Ministerio de Ciencia, Innovación y Universidades
- Fundación Instituto de Investigación Sanitaria de Santiago de Compostela
- European Commission
- Fundación Científica Asociación Española Contra el Cáncer
- Ministerio de Ciencia e Innovación
- Xunta de Galicia
- Centro de Investigación Biomédica en Red de Cáncer
- Instituto de Salud Carlos III
- Agencia Estatal de Investigación